Biotech Event Tracker

274 events

Date	Symbol	Description	Type	Disease	Designation	Success Rating
H2 2016	CCXI	ChemoCentryx (CCXI) Phase 1b Results of CCX872 for Advanced Pancreatic Cancer	Phase 1b Results	Oncology	None
Q4 2017	ARNA	Arena Pharmaceuticals (ARNA) Phase 2 Results of Etrasimod for Ulcerative Colitis	Phase 2 Results	Other	None
Q4 2016	CASC	Cascadian Therapeutics (CASC) Phase 1b Results of ONT-380 for HER2+ Breast Cancer	Phase 1b Results	Oncology	Fast Track
Q4 2016	ATRS	Antares Pharma (ATRS) NDA Submission of QuickShot Testosterone for Male Hypogonadism	NDA Submission	Endocrine	None
10/22/2016	OPK	OPKO (OPK) PDUFA of Rayaldee for Secondary Hyperparathyroidism	PDUFA	Endocrine	None
Q4 2016	ARDM	Aradigm Corporation (ARDM) Phase 3 Results of Pulmaquin for Non-Cystic Fibrosis Bronchiectasis	Phase 3 Results	Respiratory	Fast Track
Q4 2016	ANTH	Anthera Pharmaceuticals (ANTH) Top-line Phase 3 Results of Sollpura (liprotamase) for Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis	Phase 3 Results	Endocrine	None
Q4 2016	AGIO	Agios Pharmaceuticals (AGIO) NDA Submission of Enasidenib (AG-221) for Acute Myeloid Leukemia	NDA Submission	Oncology	Fast Track, Orphan Drug
Q3 2016	ACRS	Aclaris Therapeutics (ACRS) Phase 2 Results of A-101 Topical Solution for Common Warts	Phase 2 Results	Other	None
Q3 2016	AERI	Aerie Pharmaceuticals (AERI) Top-Line Phase 3 Results of Roclatan for Glaucoma	Phase 3 Results	Opthamology	None